多种癌症中免疫治疗的异质性与疗效：来自荟萃分析的启示

Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis.

本荟萃分析为免疫治疗尤其是 CAR-T 在癌症治疗中的潜力提供了有价值的见解。

双靶向 CAR-T 细胞疗法治疗复发/难治性 B 细胞淋巴系统恶性肿瘤的疗效与安全性：系统评价与 Meta 分析

Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review

疗效增强的基因修饰 CD7 靶向异体 CAR-T 细胞疗法治疗复发/难治性 CD7 阳性血液系统恶性肿瘤：一项 I 期临床研究

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancie

双暴露慢性淋巴细胞白血病与小淋巴细胞淋巴瘤患者治疗的疗效与效果结局：一项系统性文献综述

Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systemati

本研究凸显了关于双暴露 CLL/SLL 患者疗效结局的临床数据有限。

基于综合老年评估系统的人源化抗 CD19 CAR-T 细胞治疗复发/难治性弥漫大 B 细胞淋巴瘤老年患者的安全性与疗效评估

Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffu

学术性即时抗 CD19CAR-T 细胞产品 varnimcabtagene autoleucel（ARI-0001 细胞）在治疗复发/难治性 B 细胞非霍奇金淋巴瘤中显示出疗效和安全性

The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in

平衡 CAR 的激活与共刺激可调节信号动力学并增强治疗效力

Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency.

放疗预处理增强 B7-H3-CAR-T 治疗实体瘤模型的疗效

Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.

我们的结果提示，B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。

CLL1 CAR-T 细胞疗法治疗复发/难治性急性髓系白血病成年患者的最新数据

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

AFM13 治疗复发/难治性经典型霍奇金淋巴瘤：开放标签、随机、多中心 II 期试验最终结果

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.